Alpha Cognition (NASDAQ:ACOG) Upgraded at Wall Street Zen

Posted by on Aug 18th, 2026

Wall Street Zen upgraded shares of Alpha Cognition (NASDAQ:ACOG – Free Report) from a sell rating to a hold rating in a report issued on Saturday.

ACOG has been the subject of a number of other reports. Raymond James Financial started coverage on shares of Alpha Cognition in a research report on Friday, July 10th. They issued an “outperform” rating and a $20.00 target price for the company. Craig Hallum restated a “buy” rating and set a $17.00 price target on shares of Alpha Cognition in a research report on Friday. Maxim Group began coverage on shares of Alpha Cognition in a research note on Friday, May 29th. They set a “buy” rating and a $12.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Alpha Cognition in a report on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Alpha Cognition has an average rating of “Buy” and an average target price of $17.25.

Check Out Our Latest Stock Report on Alpha Cognition

Alpha Cognition Stock Performance

NASDAQ ACOG opened at $8.84 on Friday. The business has a fifty day moving average price of $7.80 and a 200 day moving average price of $6.55. The company has a market cap of $192.45 million, a P/E ratio of -8.04 and a beta of 2.30. Alpha Cognition has a one year low of $4.50 and a one year high of $10.00.

Alpha Cognition (NASDAQ:ACOG – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.01). Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%.The business had revenue of $6.00 million for the quarter, compared to analyst estimates of $4.38 million. As a group, sell-side analysts predict that Alpha Cognition will post -1.37 EPS for the current fiscal year.

Institutional Trading of Alpha Cognition

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC acquired a new stake in shares of Alpha Cognition in the 2nd quarter worth $112,000. Massar Capital Management LP acquired a new position in shares of Alpha Cognition during the 2nd quarter valued at about $116,000. Two Sigma Investments LP acquired a new position in shares of Alpha Cognition during the 3rd quarter valued at about $148,000. Connective Capital Management LLC purchased a new stake in shares of Alpha Cognition in the third quarter valued at about $312,000. Finally, ACT Capital Management LLC purchased a new stake in shares of Alpha Cognition in the fourth quarter valued at about $335,000.

About Alpha Cognition

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Read More

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.